MedTrace Logo

Feasibility Trial of Neoadjuvant Chemoradiotherapy for Locally Advanced Gastric Cancer

NCT01381913 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 12

Last updated 2011-06-27

No results posted yet for this study

Summary

Because locally far-advanced gastric cancer combined with adjacent tissue invasion has a poor prognosis, some phase 2 and 3 clinical trials of neoadjuvant chemotherapy (NAC) are performed in Japan. However, neoadjuvant chemoradiotherapy (NACRT) achieves superior local tumor control compared with NAC. This feasibility trial explored the feasibility and safety of neoadjuvant chemoradiotherapy (NACRT) in this type of gastric cancer.

Conditions

Sponsors & Collaborators

  • Kagawa University

    lead OTHER

Principal Investigators

  • Shinichi Yachida, M. D. Ph. D. · Department of Gastroenterological Surgery, Faculty of Medicine, Kagawa University, Kagawa, Japan

  • Yasuyuki Suzuki, M. D. Ph. D. · Department of Gastroenterological Surgery, Faculty of Medicine, Kagawa University, Kagawa, Japan

Eligibility

Min Age
20 Years
Max Age
80 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2005-10-31
Primary Completion
2008-12-31
Completion
2011-05-31

Countries

  • Japan

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01381913 on ClinicalTrials.gov